A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal

Project: Research project

Project Details

Effective start/end date9/26/171/1/21


  • AstraZeneca Pharmaceuticals LP (Agmt 6/12/17)